Perspective Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Perspective Therapeutics's earnings have been declining at an average annual rate of -59.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 27.8% per year.
Belangrijke informatie
-59.5%
Groei van de winst
-18.2%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -27.8% |
| Rendement op eigen vermogen | -15.3% |
| Nettomarge | -3,563.0% |
| Volgende winstupdate | 12 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Perspective Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -52 | 21 | 29 |
| 31 Mar 24 | 2 | -50 | 20 | 25 |
| 31 Dec 23 | 1 | -37 | 21 | 21 |
| 30 Sep 23 | 1 | -20 | 18 | 14 |
| 30 Jun 23 | 1 | -13 | 16 | 9 |
| 31 Mar 23 | 3 | -6 | 14 | 5 |
| 31 Dec 22 | 5 | -8 | 9 | 2 |
| 30 Sep 22 | 10 | -9 | 11 | 3 |
| 30 Jun 22 | 0 | -6 | 6 | 1 |
| 31 Mar 22 | 11 | -6 | 9 | 2 |
| 31 Dec 21 | 11 | -6 | 9 | 2 |
| 30 Sep 21 | 10 | -5 | 8 | 2 |
| 30 Jun 21 | 10 | -3 | 7 | 1 |
| 31 Mar 21 | 10 | -4 | 7 | 1 |
| 31 Dec 20 | 10 | -3 | 7 | 1 |
| 30 Sep 20 | 10 | -3 | 7 | 1 |
| 30 Jun 20 | 10 | -3 | 8 | 1 |
| 31 Mar 20 | 9 | -3 | 7 | 1 |
| 31 Dec 19 | 8 | -4 | 7 | 1 |
| 30 Sep 19 | 8 | -4 | 7 | 1 |
| 30 Jun 19 | 7 | -5 | 7 | 1 |
| 31 Mar 19 | 7 | -6 | 7 | 2 |
| 31 Dec 18 | 7 | -7 | 7 | 2 |
| 30 Sep 18 | 6 | -7 | 7 | 2 |
| 30 Jun 18 | 6 | -7 | 7 | 2 |
| 31 Mar 18 | 6 | -6 | 7 | 1 |
| 31 Dec 17 | 5 | -6 | 7 | 1 |
| 30 Sep 17 | 5 | -6 | 6 | 1 |
| 30 Jun 17 | 5 | -6 | 6 | 1 |
| 31 Mar 17 | 5 | -6 | 6 | 1 |
| 31 Dec 16 | 4 | -5 | 5 | 1 |
| 30 Sep 16 | 5 | -5 | 5 | 1 |
| 30 Jun 16 | 5 | -5 | 5 | 1 |
| 31 Mar 16 | 5 | -5 | 5 | 1 |
| 31 Dec 15 | 5 | -4 | 5 | 0 |
| 30 Sep 15 | 5 | -4 | 4 | 1 |
| 30 Jun 15 | 5 | -4 | 4 | 1 |
| 31 Mar 15 | 4 | -4 | 4 | 1 |
| 31 Dec 14 | 4 | -5 | 4 | 1 |
| 30 Sep 14 | 4 | -5 | 4 | 1 |
| 30 Jun 14 | 4 | -7 | 4 | 1 |
| 31 Mar 14 | 4 | -6 | 4 | 1 |
| 31 Dec 13 | 5 | -5 | 4 | 1 |
Kwaliteitswinsten: CATX is currently unprofitable.
Groeiende winstmarge: CATX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CATX is unprofitable, and losses have increased over the past 5 years at a rate of 59.5% per year.
Versnelling van de groei: Unable to compare CATX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CATX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: CATX has a negative Return on Equity (-15.3%), as it is currently unprofitable.